A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer
Hashimura, T.; Shirahase, T.; Inoue, T.; Yamasaki, T.; Terada, N.; Ogura, K.; Arai, Y.; Hida, S.; Ueda, T.
Hinyokika Kiyo. Acta Urologica Japonica 51(7): 439-442
2005
ISSN/ISBN: 0018-1994 PMID: 16119805 Document Number: 592459
A prospective randomized study was conducted to evaluate the efficacy of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection (TUR) of superficial bladder cancer. A total of 63 patients were randomized into two groups, the THP group and the control group. In the THP group, 30mg of THP dissolved in 50ml saline was administered 4 times intravesically for 4 consecutive days before TUR. In the control group, no instillation was performed before TUR. The patients were followed by cystoscopy and urinary cytology every 3 months.The non-recurrence rates in the THP group and control group were 54.1% versus 37.6% at I year and 40.4% versus 26.8% at 2 years, respectively (P=0.086). Time to recurrence for tumors larger than 1 cm was significantly longer in the THP group (P=0.0137). Time to recurrence for single and grade 1 + 2 tumors tended to be longer in the THP group (P=0.09, P=0.079). No significant adverse effects were observed in any patient.Our findings suggest that intravesical THP instillation prior to TUR would be effective for patients with single, low grade lesions larger than I cm of superficial bladder cancer.